Olaparib and abiraterone for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies how well the combination of olaparib and abiraterone works for men with advanced prostate cancer that has stopped responding to hormone therapy. If you are already taking or planning to take this combination, researchers want to learn more about its long-term benefits and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 years or older with prostate cancer that has spread to other parts of the body.
- Your cancer has stopped responding to standard hormone therapy (castration-resistant).
- You have been treated with a next-generation hormone agent (such as enzalutamide or abiraterone) before.
- You are already taking or are about to start the combination of olaparib and abiraterone as your first treatment for castration-resistant prostate cancer.
- You have not taken any PARP inhibitor (like olaparib, rucaparib, niraparib, or talazoparib) before.
- You have not taken abiraterone for earlier stages of prostate cancer (before it became castration-resistant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, TY-302, combined with abiraterone (a standard hormone therapy) for men with metastatic castration-resistant prostate cancer that has stopped responding to one prior new hormone therapy. The goal is to see if the combination can help control the disease.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial is for people with advanced prostate cancer (mCRPC) who are already taking the combination of olaparib and abiraterone. It will look at how these two medicines work together in real-world practice.
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
This trial tests a new drug combination (BL-B01D1) for men with advanced prostate cancer that has stopped responding to hormone therapy. The study aims to see if this treatment can slow cancer growth and improve survival.
This trial combines three treatments—a targeted radioactive therapy (177Lu-PSMA), a PARP inhibitor (olaparib), and an immunotherapy (pembrolizumab)—to see if they work better together against advanced prostate cancer that has stopped responding to hormone therapy. You may join if your cancer shows strong PSMA on scans and you have already tried certain hormone blockers but your cancer continued to grow.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.